Gregory A. Smallwood, PharmD, FCCP
Chair and Associate Professor of Pharmacy Practice
PharmD, University of Georgia College of Pharmacy, 2001
BS (Phr), University of Georgia College of Pharmacy,1979
Dr. Smallwood has over 30 years experience as a practicing hospital pharmacist with
15 years as a clinical pharmacy specialist with a liver transplant team. He comes
to PCOM School of Pharmacy from the School of Medicine at Emory University. He has
published over 40 peer-reviewed articles, has made numerous national and international
scientific presentations, is on the editorial board of Annals of Pharmacotherapy,
and is a grant reviewer for the country of Qatar.
Dr. Smallwood currently coordinates several courses within the School of Pharmacy.
He teaches the Clinical Pharmacy course for P3 students as well as coordinates the
Sterile Laboratory associated with this course. He also teaches in several of the
integrated therapeutics courses for the P3 students. For the P2 students in the School
of Pharmacy he coordinates Pharmacokinetics.
Dr. Smallwood has been an investigator or co-investigator of more than 40 human clinical
trials. His research interest includes immunology, transplant, and diabetes with his
most recent work being with the Immune Tolerance Network (ITN) using immunosuppressants
in treating Type 1 diabetes which is funded by the National Institute of Allergy and
Infectious Disease (NIAID) of the National Institute of Health (NIH).
Elected as a Fellow of the American College of Clinical Pharmacy (ACCP). October 21,
2012 at the 2012 Annual Meeting in Hollywood, Florida.
President Choice Award, Emergence of drug resistance cytomegalovirus following liver
transplantation. American Association for the Study of Liver Disease (AASLD) annual
meeting. November 12-15, 2005; San Francisco, CA
Recipient of an Award of Excellence in Pharmacy. Relationship between immunosuppression
and osteoporosis in an outpatient liver transplant clinic. 3rd International Congress
on Immunosuppression. December, 2004 - Manchester Grand Hyatt San Diego, San Diego,
President Choice Award, Increased survival in pediatric acute hepatic failure following
liver transplantation with early surgical intervention utilizing living donor, partial
grafts, and ABO incompatible grafts. American Association for the Study of Liver Disease
(AASLD) annual meeting. November 2005; San Francisco, CA
Heffron TG. Pillen T. Smallwood G. Henry S. Sekar S. Solis D. Casper K. Fasola C. Romero R. Liver re-transplantation
in children: the Atlanta experience. Pediatric Transplantation. 14(3):417-25, 2010
Heffron TG, Pillen T, Smallwood G, Rodriguez J, Sekar S, Henry S, Vos M, Casper K, Gupta N, Fasola CG, Romero R. Pediatric
liver transplantation for acute liver failure at a single center: a ten-year experience.
Pediatric Transplantation; 14:228-232, 2010.
Gregory A. Smallwood, Renee Devine, Carlos Fasola, Andrei Stieber, and Thomas G. Heffron. Does interferon
use prior to liver transplant influence hepatitis C outcomes following transplantation?
Transplantation. 86(12):1795-1798, 2008 Dec
Nature Reviews Gastroenterology & Hepatology, 6:194, 2009 April
Gregory A. Smallwood. Immunosuppressive strategies to avoid complications: the Achilles’ heel of transplantation.
Current Opinion in Organ Transplantation Vol. 11, No. 6; 613-20. 2006
Jenny Bell & Gregory A. Smallwood. Current issues and treatment strategies for female transplant recipients. Graft
Vol. 7, No. 4, pg. 233-46, June 2005
GA Smallwood, D. Burns, C Fasola, AC Stieber, TG Heffron. Relationship between immunosuppression
and osteoporosis in an outpatient liver transplant clinic Transplant Proceedings,
37, 1910-11, 2005 May
GA Smallwood, L Davis, K Connor, E Martinez, AC Stieber, and TG Heffron Nonresponders of Interferon/Ribavirin
Treatment for Recurrent Hepatitis C Following Liver transplantation. Transplantation
Proceedings. 35(4): 1476-7, 2003 June
Should the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation be
used to evaluate renal function in the hepatic failure patient awaiting liver transplantation?
Gregory Smallwood, B.S., Phr., Pharm.D. ACCP Annual Meeting, Platform Presentation (oral) and Judged to be in the top 8 out of 554 submitted abstracts
for the conference; Hollywood, Fl. Pharmacotherapy 2012; 32(10); e179
Is valganciclovir a viable option for cytomegalovirus (CMV) prophylaxis in liver transplantation?
Gregory Smallwood, B.S., Pharm.D. 2011 ACCP Annual Meeting, Platform Presentation (oral); Pittsburg, Pa. Pharmacotherapy 2011; 31(10); 386e
Cytomegalovirus infection in the pediatric liver transplant recipient. GA Smallwood,
K Casper, T Barnett, T Heffron .Platform Presentation (oral) 2010 ACCP Annual Meeting; Austin, TX. Pharmacotherapy 2010; 30(10); 415e
The evaluation of renal clearance calculations for hepatic failure patients awaiting
liver transplantation.G. Smallwood, C. Stearns, T. Heffron. 2008 ACCP Annual Meeting; Platform Presentation (oral); Kentucky International Convention Center; Lexington, KY
Preemptive vs. prophylactic approach to cytomegalovirus in liver transplantation.
G. Smallwood, K. Kempton, A. Stieber, C. Fasola, T. Heffron. XXII International Congress
of the Transplantation Society. Platform Presentation (oral); Sydney Convention Center Sydney, Australia; Transplantation, July 2008, Vol. 86,
2S; pg 248
Does interferon use prior to liver transplant influence hepatitis C outcomes following
transplantation? G. Smallwood, A. Stieber, C. Fasola, T. Heffron. XXII International
Congress of the Transplantation Society;Platform Presentation (oral) with award; Sydney Convention Center; Sydney, Australia; Transplantation, July 2008,
Vol. 86, 2S; pg 63
Ten year experience with preemptive approach to CMV infection in pediatric liver transplantation.
G. Smallwood, T. Pillen, R. Romero, T. Heffron. XXII International Congress of the
Transplantation Society.Platform Presentation (oral); Sydney Convention Center; Sydney, Australia; Transplantation, July 2008, Vol. 86,
2S; pg 177
Long term Calcineurin sparing with daclizumab used in an outpatient liver transplant
clinic. G. Smallwood, K. Kempton, A. Stieber, C. Fasola, T. Heffron. XXII International
Congress of the Transplantation Society.Platform Presentation (oral); Sydney Convention Center; Sydney, Australia; Transplantation, July 2008, Vol. 86,
2S; pg 128
Volunteer & Leadership
Community Advisory Panel (CAP) Member for the PBRN (Practice Based Research Network)
of the American College of Clinical Pharmacist (ACCP)
Member of the Institutional Review Board (IRB), Biomedical Committee Emory University,
Frontiers – PRN Representative, American College of Clinical Pharmacist (ACCP)
Planning committee for the Immune Tolerance Network (ITN) sponsored by NIAID entitled:
ITN045AI: Multicenter, randomized trial entitled: Inducing Remission in New Onset
T1DM with Alefacept (Amevive®).
International Committee member to develop a non-adherence consensus statement in solid
organ transplantation for the American Society of Transplantation(AST), American Society
of Transplant Surgeons(ASTS), and the International Pediatric Transplant Society(IPTS)
Enhancing Wellness: Lifelong Success for the Transplant Patient website. Health Maintenance
Committee, American Society of Transplantation (AST). November 2005
Planning committee member for the Baylor HCV project following liver transplantation
sponsored by Baylor Medical Center and Roche
A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver
Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day
to Prograf® Capsules Twice-A-Day - Sponsored by Lifecycle Pharma
An Open Label Phase II Extension Study for Patients Completing Study LCP-Tacro 2012
(An Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant
Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf®
Capsules Twice-A-Day) – Sponsored by Lifecycle Pharma
“Comparison of mycophenolate mofetil (CellCept®) pharmacokinetics of mycophenolic
acid (MPA) to enteric coated mycophenolate sodium (Myfortic®) in stable, long-term
liver transplant recipients - Sponsored by F. Hoffmann-La Roche Ltd.
“A randomized, controlled, multicenter study of Thymoglobulin induction therapy with
a calcineurin-inhibitor sparing regimen in liver transplant patients.” - Sponsored
by SangStat Medical Corporation